Us Drugmaker
May 16, 2012 at 10:42 | Source: Reuters
May 11, 2012 at 04:52 | Source: Reuters
May 09, 2012 at 15:36 | Source: Reuters
May 03, 2012 at 15:26 | Source: Reuters
Apr 23, 2012 at 11:42 | Source: Reuters
Apr 23, 2012 at 11:02 | Source: Reuters
News across the web »
May 07, 2012 at 12:42 | Source: Economic Times
May 03, 2012 at 16:41 | Source: FirstPost
Apr 24, 2012 at 12:01 | Source: Stock Market Digital
Apr 24, 2012 at 06:11 | Source: FirstPost
Apr 24, 2012 at 02:16 | Source: Business Standard
Interact & exchange stock tips & market info »
Related News »
Indian drugmaker Piramal Healthcare on Wednesday said it will buy US-based health data provider Decision Resources Group for $635 million to boost its presence in research and consulting. The cash-rich firm has been scouting for business opportunities ...
May 16, 2012 at 19:13 | Source: YAHOO!
(Reuters) - U.S. generic drug maker Mylan Inc settled a patent infringement suit with Sunovion Pharmaceuticals Inc, a unit of Dainippon Sumitomo Pharma Co, related to the Japanese drugmaker's bronchitis medicine Brovana. Mylan said Sunovion has ...
May 24, 2012 at 22:31 | Source: Reuters UK
LONDON (Reuters) - Takeda Pharmaceutical (4502.T), Japan's top drugmaker, is to buy Brazil's Multilab for up to 540 million Brazilian reals ($265 million) in a deal highlighting global drugmakers' appetite for emerging market sales. Frank Morich ...
May 25, 2012 at 11:10 | Source: Reuters
J&J developed the drug in partnership with German drugmaker Bayer AG . The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by the end of June.
May 23, 2012 at 20:16 | Source: Reuters
Drugmaker Piramal Healthcare is buying US-based healthcare data provider for $635 million to boost research and development. Mumbai-based Piramal Healthcare, controlled by billionaire Ajay Piramal, has been looking to expand its R&D portfolio after it sold ...
May 16, 2012 at 15:53 | Source: Deccan Herald
and as the Indian drugmaker faced a US import ban. Daiichi has not made as much money in the four years since it bought Ranbaxy as it did in the quarter before the acquisition. The basic problem, say bankers, is a lack of restraint – both in financial ...
May 24, 2012 at 18:42 | Source: Financial Times
(Reuters) - Human Genome Sciences Inc said on Thursday it adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion hostile takeover bid by drugmaker GlaxoSmithKline Plc. Human Genome said its board ...
May 17, 2012 at 17:46 | Source: Reuters India
Under the previous management, KAEF expanded from a drugmaker to a healthcare provider ... During the annual meeting, KAEF announced that it would pay out Rp 34.35 billion (US$37 million), or 20 percent of its 2011 net profits of Rp 171.76 ...
May 25, 2012 at 03:03 | Source: Jakarta Post
Tafamidis has fast track designation in the US, by the way. Despite the potential for a setback ... diseases caused by so-called protein misfolding. And in doing so, the drugmaker can also point its pursuit of a treatment for a rare disease.
May 23, 2012 at 17:39 | Source: Forbes
Chronic hepatitis B infection can result in liver cirrhosis and liver cancer later in life. The French drugmaker is uncertain what percentage of liver cancer patients in China may respond to the therapy. "But in China, even 10 percent of liver ...
May 24, 2012 at 09:17 | Source: Reuters India